Day One Biopharmaceuticals Stock Performance
| DAWN Stock | USD 11.16 0.34 2.96% |
On a scale of 0 to 100, Day One holds a performance score of 6. The firm shows a Beta (market volatility) of 0.57, which means possible diversification benefits within a given portfolio. As returns on the market increase, Day One's returns are expected to increase less than the market. However, during the bear market, the loss of holding Day One is expected to be smaller as well. Please check Day One's downside variance, as well as the relationship between the accumulation distribution and price action indicator , to make a quick decision on whether Day One's price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Day One Biopharmaceuticals are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Day One displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 3.05 | Five Day Return (7.11) | Year To Date Return 29.94 | Ten Year Return (51.06) | All Time Return (51.06) |
1 | Disposition of 90000 shares by Adam Dubow of Day One at 23.41 subject to Rule 16b-3 | 11/06/2025 |
2 | Disposition of 3570 shares by Bender Jeremy of Day One subject to Rule 16b-3 | 11/14/2025 |
3 | Disposition of 7225 shares by Bender Jeremy of Day One subject to Rule 16b-3 | 11/25/2025 |
4 | Acquisition by Bender Jeremy of 300000 shares of Day One subject to Rule 16b-3 | 11/26/2025 |
5 | Day One Biopharmaceuticals Target of Unusually Large Options Trading | 12/17/2025 |
6 | Day One Biopharmaceuticals Stock Pre-Market Market Digests Mersana Acquisition - Trefis | 01/09/2026 |
7 | Day One Biopharmaceuticals Announces Strong OJEMDA Revenue Outlook - TipRanks | 01/12/2026 |
8 | A Look At Day One Biopharmaceuticals Valuation After Strong OJEMDA Revenue Update And 2026 Sales Guidance | 01/13/2026 |
9 | Day One Biopharmaceuticals Is Up 11.7 percent After Strong OJEMDA 2025 Sales And 2026 Outlook - Has The Bull Case Changed | 01/15/2026 |
10 | Optimistic Investors Push Day One Biopharmaceuticals, Inc. Shares Up 31 percent But Growth Is Lacking | 01/21/2026 |
11 | Acquisition by Bender Jeremy of 1463134 shares of Day One at 8.99 subject to Rule 16b-3 | 01/28/2026 |
12 | Acquisition by Adam Dubow of 70000 shares of Day One subject to Rule 16b-3 | 01/30/2026 |
13 | Wall Street Analysts See a 101.08 percent Upside in Day One Biopharmaceuticals Can the Stock Really Move This High | 02/02/2026 |
| Begin Period Cash Flow | 230.8 M | |
| Total Cashflows From Investing Activities | -231 M |
Day One Relative Risk vs. Return Landscape
If you would invest 914.00 in Day One Biopharmaceuticals on November 5, 2025 and sell it today you would earn a total of 202.00 from holding Day One Biopharmaceuticals or generate 22.1% return on investment over 90 days. Day One Biopharmaceuticals is currently generating 0.5054% in daily expected returns and assumes 6.1994% risk (volatility on return distribution) over the 90 days horizon. In different words, 55% of stocks are less volatile than Day, and 90% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Day One Target Price Odds to finish over Current Price
The tendency of Day Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 11.16 | 90 days | 11.16 | about 9.82 |
Based on a normal probability distribution, the odds of Day One to move above the current price in 90 days from now is about 9.82 (This Day One Biopharmaceuticals probability density function shows the probability of Day Stock to fall within a particular range of prices over 90 days) .
Day One Price Density |
| Price |
Predictive Modules for Day One
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Day One Biopharmaceu. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Day One's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Day One Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Day One is not an exception. The market had few large corrections towards the Day One's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Day One Biopharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Day One within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.86 | |
β | Beta against Dow Jones | 0.57 | |
σ | Overall volatility | 1.37 | |
Ir | Information ratio | 0.12 |
Day One Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Day One for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Day One Biopharmaceu can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Day One Biopharmaceu is way too risky over 90 days horizon | |
| Day One Biopharmaceu appears to be risky and price may revert if volatility continues | |
| Day One Biopharmaceu has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 131.16 M. Net Loss for the year was (95.5 M) with profit before overhead, payroll, taxes, and interest of 119.56 M. | |
| Day One Biopharmaceuticals currently holds about 394.86 M in cash with (78.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.38. | |
| Day One Biopharmaceu has a poor financial position based on the latest SEC disclosures | |
| Over 86.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Wall Street Analysts See a 101.08 percent Upside in Day One Biopharmaceuticals Can the Stock Really Move This High |
Day One Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Day Stock often depends not only on the future outlook of the current and potential Day One's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Day One's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 93.6 M | |
| Cash And Short Term Investments | 531.7 M |
Day One Fundamentals Growth
Day Stock prices reflect investors' perceptions of the future prospects and financial health of Day One, and Day One fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Day Stock performance.
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.19 | ||||
| Profit Margin | (1.14) % | ||||
| Operating Margin | (0.61) % | ||||
| Current Valuation | 697.17 M | ||||
| Shares Outstanding | 102.68 M | ||||
| Price To Earning | 3.88 X | ||||
| Price To Book | 2.54 X | ||||
| Price To Sales | 8.57 X | ||||
| Revenue | 131.16 M | ||||
| Gross Profit | 119.56 M | ||||
| EBITDA | (86.32 M) | ||||
| Net Income | (95.5 M) | ||||
| Cash And Equivalents | 394.86 M | ||||
| Cash Per Share | 5.38 X | ||||
| Total Debt | 2.6 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 31.45 X | ||||
| Book Value Per Share | 4.39 X | ||||
| Cash Flow From Operations | (78.11 M) | ||||
| Earnings Per Share | (1.52) X | ||||
| Market Capitalization | 1.15 B | ||||
| Total Asset | 582.79 M | ||||
| Retained Earnings | (554.08 M) | ||||
| Working Capital | 488.88 M | ||||
About Day One Performance
By examining Day One's fundamental ratios, stakeholders can obtain critical insights into Day One's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Day One is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 206.66 | 183.70 | |
| Return On Tangible Assets | (0.15) | (0.16) | |
| Return On Capital Employed | (0.49) | (0.52) | |
| Return On Assets | (0.16) | (0.15) | |
| Return On Equity | (0.22) | (0.23) |
Things to note about Day One Biopharmaceu performance evaluation
Checking the ongoing alerts about Day One for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Day One Biopharmaceu help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Day One Biopharmaceu is way too risky over 90 days horizon | |
| Day One Biopharmaceu appears to be risky and price may revert if volatility continues | |
| Day One Biopharmaceu has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 131.16 M. Net Loss for the year was (95.5 M) with profit before overhead, payroll, taxes, and interest of 119.56 M. | |
| Day One Biopharmaceuticals currently holds about 394.86 M in cash with (78.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.38. | |
| Day One Biopharmaceu has a poor financial position based on the latest SEC disclosures | |
| Over 86.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Wall Street Analysts See a 101.08 percent Upside in Day One Biopharmaceuticals Can the Stock Really Move This High |
- Analyzing Day One's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Day One's stock is overvalued or undervalued compared to its peers.
- Examining Day One's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Day One's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Day One's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Day One's stock. These opinions can provide insight into Day One's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Day One Biopharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Will Biotechnology sector continue expanding? Could Day diversify its offerings? Factors like these will boost the valuation of Day One. Projected growth potential of Day fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Day One data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.52) | Revenue Per Share | Quarterly Revenue Growth (0.58) | Return On Assets | Return On Equity |
Investors evaluate Day One Biopharmaceu using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Day One's intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Day One's market price to deviate significantly from intrinsic value.
It's important to distinguish between Day One's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Day One should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Day One's market price signifies the transaction level at which participants voluntarily complete trades.